Protocol Ledger

NCT03969329 · Phase III · RECRUITING

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Interventional Phase III clinical trial protocol NCT03969329 sponsored by Amgen in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-12-20 Enrollment: 24 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03969329
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03969329
Protocol FieldVerified Registry Value
NCT IdentifierNCT03969329
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment24 participants (ESTIMATED)
Registered Start Date2019-12-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03969329
Hospital Research SiteLocationSite Profile
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->
Fakultni nemocnice v MotolePrague, CzechiaOpen Hospital Dossier ->
Universitaetsklinikum Hamburg EppendorfHamburg, GermanyOpen Hospital Dossier ->
Medizinische Hochschule HannoverHanover, GermanyOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI